
Dr. Gao on study of resistance to PARP inhibitor olaparib in prostate cancer
“In those resistance cells, there is a lot of senescence occurring there, so that provides some potential target…which can be used to improve those PARP inhibitor therapies,” says Allen C. Gao, MD, PhD.
In this video, Allen C. Gao, MD, PhD, discusses the background and findings of the study, “
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


















